

FILE 'HOME' ENTERED AT 09:00:30 ON 08 DEC 2008

=> FIL REGISTRY

FILE 'REGISTRY' ENTERED AT 09:00:39 ON 08 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

DICTIONARY FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

```
[RK] [ARNQGHILKMFPSTWVY] C[AGS] [TAGS] [HILMFPTVWY] [HILMFPTVWY] [AGSHILMFPTVWYNQ] [ARNQGHILKMFPSTWVY] [RKHILMFPTVWYNQ] [HILMFPTVWY] [HILMFPTVWY] [HILMFPTVWY] [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ] C[AGSHILMFPTVWY] /SQSP
```

```
L1      0 [RK] [ARNQGHILKMFPSTWVY] C[AGS] [TAGS] [HILMFPTVWY] [HILMFPTVWY] [AGSHILMFPTVWYNQ] [ARNQGHILKMFPSTWVY] [RKHILMFPTVWYNQ] [HILMFPTVWY] [HILMFPTVWY] [HILMFPTVWY] [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ] C[AGSHILMFPTVWY] /SQSP
```

=>

```
[ANRQGHILKMFPSTWYV] C([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ] C[AGSHILMFPTVWY] /SQSP
```

```
L2      4577 [ANRQGHILKMFPSTWYV] C([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ] C[AGSHILMFPTVWY] /SQSP
```

=> 12 and sql<=29

6887764 SQL<=29

L3 32 L2 AND SQL<=29

=>

```
^. {1-5} [ANRQGHILKMFPSTWYV] C([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ] C[AGSHILMFPTVWY] . {1-5} /SQSP
```

```
L4      37 ^. {1-5} [ANRQGHILKMFPSTWYV] C([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] (
```

[HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYN
Q]C[AGSHILMFPTVWY] . {1-5}/SQSP

=>

^. {2-5} [ANRQGHILKMFPSTWYV]C ({AGS}) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKM
FPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHI
LMFPTVWY] [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY] . {1-5}/SQSP

L5 35 ^. {2-5} [ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGS
HILMFPTVWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] (
[HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYN
Q]C[AGSHILMFPTVWY] . {1-5}/SQSP

=>

[ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV
] [PRQ] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTV
WYNQ]C[AGSHILMFPTVWY]/SQSP

L6 1428 [ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPT
VWYANRQGHILKMFPSTWYV] [PRQ] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHIL
MFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQ
SP

=>

[ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV
] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVW
Y] [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY] [RA]/SQSP

L7 277 [ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPT
VWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPT
VWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ]C[AGS
HILMFPTVWY] [RA]/SQSP

=>

[ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV
] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVW
Y] [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]Q/SQSP

L8 251 [ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPT
VWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPT
VWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ]C[AGS
HILMFPTVWY]Q/SQSP

=>

[ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPTVWYANRQGHILKMFPSTWYV
] [ANRQGHILKMFPSTWYV] [NQ] ([HILMFPTVWY]) {3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPT
VWYNQ]C[AGSHILMFPTVWY]/SQSP

L9 1447 [ANRQGHILKMFPSTWYV]C ([AGS]) {2} [TAGS] ([HILMFPTVWY]) {2} [AGSHILMFPT
VWYANRQGHILKMFPSTWYV] [ANRQGHILKMFPSTWYV] [NQ] ([HILMFPTVWY]) {3} [SH
ILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/
SQSP

=> 12 and sql=<44

8728334 SQL=<44

L10 35 L2 AND SQL=<44

=> 110 and 16

L11 12 L10 AND L6

=> 110 and 17

L12 11 L10 AND L7

=> l10 and l8

L13 19 L10 AND L8

=> l10 and l9

L14 5 L10 AND L9

=> l11 or l12 or l13 or l14

L15 33 L11 OR L12 OR L13 OR L14

=> FIL CAPLUS

FILE 'CAPLUS' ENTERED AT 09:08:37 ON 08 DEC 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2008 VOL 149 ISS 24

FILE LAST UPDATED: 7 Dec 2008 (20081207/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> l15

L16 26 L15

=> l16 and pd<=20030814

23849345 PD<=20030814

(PD<=20030814)

L17 17 L16 AND PD<=20030814

=> l16 and prd<=20030814

4147234 PRD<=20030814

(PRD<=20030814)

L18 15 L16 AND PRD<=20030814

=> l16 and (pd<=20020814 or prd<=20020814)

22810451 PD<=20020814

(PD<=20020814)

3855329 PRD<=20020814

(PRD<=20020814)

L19 20 L16 AND (PD<=20020814 OR PRD<=20020814)

=> d 119 1-20 ibib hitseq

L19 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:20444 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 140:110119

TITLE: Mammalian EPO mimetic CH1 deleted mimetibodies,
compositions, methods and uses for diagnosis and
therapy of human diseases

INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John;
Scallion, Bernard J.; Nesspor, Thomas C.; Kutoloski,
Karen A.

PATENT ASSIGNEE(S): Centocor, Inc., USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002424	A2	20040108	WO 2003-US20495	20030630 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490411	A1	20040108	CA 2003-2490411	20030630 <--
AU 2003256336	A1	20040119	AU 2003-256336	20030630 <--
BR 2003012276	A	20050426	BR 2003-12276	20030630 <--
US 20050191301	A1	20050901	US 2003-609783	20030630
US 7241733	B2	20070710		
EP 1575499	A2	20050921	EP 2003-762210	20030630 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005536992	T	20051208	JP 2004-518080	20030630 <--
CN 1735433	A	20060215	CN 2003-820110	20030630 <--
IN 2004KN01988	A	20060707	IN 2004-KN1988	20041224 <--
MX 2005PA00202	A	20050930	MX 2005-PA202	20050103 <--
PRIORITY APPLN. INFO.:			US 2002-392431P	P 20020628 <--
			US 2002-412144P	P 20020919
			WO 2003-US20495	W 20030630

IT **645406-06-0**

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence, mimetibody comprising; mammalian EPO mimetic CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)


RN 645406-06-0 CAPLUS




CN L-Alanine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFQGGG LIHARFVMTA ASCFA 25


Absolute stereochemistry.

PAGE 1-A







PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 2000:210198 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 132:218021
 TITLE: Cloning and cDNA and deduced amino acid sequences of
 31 human secreted proteins
 INVENTOR(S): Ruben, Steven M.; Rosen, Craig A.; Duan, Roxanne D.;
 Shi, Yanggu; Lafleur, David W.; Young, Paul E.; Ni,
 Jian; Komatsoulis, George; Endress, Gregory A.;
 Soppet, Daniel R.
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; et al.
 SOURCE: PCT Int. Appl., 416 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017222	A1	20000330	WO 1999-US22012	19990922 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2344100	A1	20000330	CA 1999-2344100	19990922 <--
AU 9959288	A	20000410	AU 1999-59288	19990922 <--
EP 1115735	A1	20010718	EP 1999-946997	19990922 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526059	T	20020820	JP 2000-574130	19990922 <--
US 20020076705	A1	20020620	US 2001-820893	20010330 <--
US 20040048294	A1	20040311	US 2003-607565	20030627 <--
PRIORITY APPLN. INFO.:				
			US 1998-101546P	P 19980923 <--
			US 1998-102895P	P 19981002 <--
			WO 1999-US22012	W 19990922 <--
			US 2000-531119	B1 20000320 <--
			US 2001-820893	B1 20010330 <--

IT **261164-15-2**

RL: PRP (Properties)

(unclaimed sequence; cloning and cDNA and deduced amino acid sequences
 of 31 human secreted proteins)


RN 261164-15-2 CAPLUS

CN L-Tryptophan, L-threonyl-L-cysteinyglycylglycyl-L-seryl-L-valyl-L-leucyl-
 L-alanyl-L-prolyl-L-arginyl-L-tryptophyl-L-valyl-L-valyl-L-threonyl-L-
 alanyl-L-alanyl-L-histidyl-L-cysteiny-L-methionyl-L-histidyl-L-seryl-L-
 phenylalanyl-L-arginyl-L-leucyl-L-alanyl-L-arginyl-L-leucyl-L-seryl-L-
 seryl- (9CI) (CA INDEX NAME)



SEQ 1 TCGGSVLAPR WVTAAHCHM SFRLARLSSW




Absolute stereochemistry.

PAGE 1-A




PAGE 1-B






PAGE 2-C



PAGE 2-D



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:601254 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:306552
ORIGINAL REFERENCE NO.: 127:59951a
TITLE: Interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes
AUTHOR(S): Polikandritou Lambros, Maria; Sheu, Eric; Lin, J. S.; Pereira, H. Anne
CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
SOURCE: Biochimica et Biophysica Acta, Biomembranes (1997), 1329(2), 285-290
CODEN: BBBMBS; ISSN: 0005-2736
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 151679-59-3P

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes)


RN 151679-59-3 CAPLUS




CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)



SEQ 1 NQGRHFCCGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A







REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:408609 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 127:148252

ORIGINAL REFERENCE NO.: 127:28629a

TITLE: A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats

AUTHOR(S): Brackett, Daniel J.; Lerner, Megan R.; Lacquement, Melissa A.; He, Rong; Pereira, H. Anne

CORPORATE SOURCE: Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73190, USA

SOURCE: Infection and Immunity (1997), 65(7), 2803-2811

CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 151679-59-3

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(synthetic lipopolysaccharide-binding peptide based on
neutrophil-derived protein CAP37 prevents endotoxin-induced responses
in conscious rats)


RN 151679-59-3 CAPLUS




CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A








REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L19 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:344807 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 127:13456
 ORIGINAL REFERENCE NO.: 127:2623a,2626a
 TITLE: Method and composition for the treatment of septic shock
 INVENTOR(S): Pereira, Heloise A.
 PATENT ASSIGNEE(S): University of Oklahoma, USA
 SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,607,916.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PAGE 1-B



PAGE 2-A





L19 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:204303 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 126:207540

ORIGINAL REFERENCE NO.: 126:40001a

TITLE: Method and composition using
lipopolysaccharide-binding peptide derived from CAP37
protein for the treatment of septic shock

INVENTOR(S): Pereira, Heloise A.; Brackett, Daniel J.; Lerner,
Megan R.

PATENT ASSIGNEE(S): Board of Regents of the University of Oklahoma, USA
SOURCE: U.S., 19 pp., Cont.-in-part of U.S. 5,458,874.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

-----	-----	-----	-----	-----
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
US 5650392	A	19970722	US 1995-455485	19950531 <--
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:			US 1989-375739	B2 19890705 <--
			US 1990-543151	B2 19900625 <--
			US 1992-855417	A1 19920319 <--
			US 1992-969931	A2 19921030 <--
			US 1992-939931	A2 19921030 <--
			US 1994-235399	A3 19940429 <--
			US 1995-482328	A1 19950607 <--
			US 1997-840519	A1 19970421 <--

IT **151679-59-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lipopolysaccharide-binding peptide derived from CAP37 protein for the treatment of septic shock)


RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)




SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ



Absolute stereochemistry.

PAGE 1-A



•





L19 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:8914 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 126:56203
 ORIGINAL REFERENCE NO.: 126:10991a,10994a
 TITLE: Isolation and characterization of a peptide from
 funnel web spider (*Agelenopsis aperta*) venom
 INVENTOR(S): Yomo, Yasushi; Kuwata, Manabu; Teramoto, Tetsuyuki;
 Niitome, Tetsuhiro; Sawada, Kohei; Nishizawa, Yukio
 PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

JP 08253499 A 19961001 JP 1994-328130 19941228 <--
PRIORITY APPLN. INFO.: JP 1994-328130 19941228 <--

IT **184786-10-5P**

RL: PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; isolation and characterization of a peptide from funnel web spider (*Agelenopsis aperta*) venom)

RN 184786-10-5 CAPLUS

CN Protein (*Agelenopsis aperta* venom agatoxin-like) (9CI) (CA INDEX NAME)

NTE multichain

SEQ 1 IVGGKTAKFG DYPWMVSIQQ KNKKGTFDHI CGGAIINVNW ILTAHCFDQ
51 PIVKSDYRAY VGLRSILHTK ENTVQRLELS KIVLHPGYKP KKDPDDIALI
101 KVAKPIVIGN YANGICVPKG VTNPEGNATV IGWGKISSGG KQVNTLQEV
151 IPIIPWKKCK EIYGDEFSEF EYSQITPYMI CAGAEGKDSC QADSGGPLFQ
201 IDANGVATLI GTVANGADCG YKHYPGVYMK VSSYTNWMSK NMV

1 VEVATVKNCG KKLLATPR

L19 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:137923 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 124:315067

ORIGINAL REFERENCE NO.: 124:58442h,58443a

TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37

INVENTOR(S): Pereira, Heloise A.; Spitznagel, John K.

PATENT ASSIGNEE(S): Emory University, USA

SOURCE: U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 543,151, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--

W: AU, CA, JP

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

AU 9348089	A	19931021	AU 1993-48089	19930319 <--
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5650392	A	19970722	US 1995-455485	19950531 <--
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--

PRIORITY APPLN. INFO.:
US 1989-375739 B2 19890705 <--
US 1990-543151 B2 19900625 <--
US 1992-855417 A1 19920319 <--
US 1992-939931 A2 19921030 <--

US 1992-969931	A2 19921030 <--
WO 1993-US2580	A 19930319 <--
US 1994-235399	A3 19940429 <--
US 1995-482328	A1 19950607 <--
US 1997-840519	A1 19970421 <--

IT **151679-59-3P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(chemotactic/antibiotic/lipopolysaccharide-binding peptide fragments of CAP37 for treating wounds, tumors, and infections)


RN 151679-59-3 CAPLUS



CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFVM TA ASCFQ

Absolute stereochemistry.

PAGE 1-A







L19 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:32761 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 124:114140
 ORIGINAL REFERENCE NO.: 124:21195a,21198a
 TITLE: A cationic antimicrobial peptide enhances the infectivity of *Coxiella burnetii*
 AUTHOR(S): Aragon, A. S.; Pereira, H. A.; Baca, O. G.
 CORPORATE SOURCE: Biology Department, University of New Mexico, Albuquerque, NM, 8713-1091, USA
 SOURCE: Acta Virologica (English Edition) (1995), 39(4), 223-6
 CODEN: AVIRA2; ISSN: 0001-723X
 PUBLISHER: Slovak Academic Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT **151679-59-3**
 RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (CAP3720-44 (a synthetic peptide based on the 37-Kd human neutrophil

granule-associated cationic antimicrobial protein, CAP37) enhances the infectivity of *Coxiella burnetii*)


RN 151679-59-3 CAPLUS



CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A










L19 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:17399 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 124:84820
 ORIGINAL REFERENCE NO.: 124:15949a,15952a
 TITLE: Sperm immobilizing activity of a synthetic bioactive peptide 20-44 of 37-kDa cationic antimicrobial protein (CAP37) of human neutrophils
 AUTHOR(S): D'Cruz, Osmond J.; Pereira, H. Anne; Haas, Gilbert G. Jr.
 CORPORATE SOURCE: Health Sciences Center, University Oklahoma, Oklahoma City, OK, 73190, USA
 SOURCE: Journal of Andrology (1995), 16(5), 432-40
 CODEN: JOAND3; ISSN: 0196-3635
 PUBLISHER: American Society of Andrology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 151679-59-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological



(sperm immobilization by peptide 20-44 fragment of CAP37 of human neutrophils)

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.





L19 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:563 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 120:563
 ORIGINAL REFERENCE NO.: 120:135a,138a
 TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding
 peptide fragments of CAP37
 INVENTOR(S): Pereira, Heloise Anne; Spitznagel, John K.
 PATENT ASSIGNEE(S): Emory University, USA
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--

W: AU, CA, JP
 RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
 US 5484885 A 19960116 US 1992-855417 19920319 <--
 AU 9348089 A 19931021 AU 1993-48089 19930319 <--
 PRIORITY APPLN. INFO.: US 1992-855417 A 19920319 <--
 US 1989-375739 B2 19890705 <--
 US 1990-543151 B2 19900625 <--
 WO 1993-US2580 A 19930319 <--

IT 151705-32-7 151769-18-5 152699-65-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (bactericidal activity of)


RN 151705-32-7 CAPLUS



CN L-Glutamine, L-asparaginyll-L-glutaminyl-L-glutaminyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 NQQRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A







RN 151769-18-5 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ


RN 152699-65-5 CAPLUS

CN L-Glutamine, L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 FCGGALIHAR FVMTAASCFO


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





IT. **151679-59-3**

RL: BIOL (Biological study)



(of chemotactic protein, of neutrophil, bactericidal and lipopolysaccharide-binding activity of)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 119:115274
ORIGINAL REFERENCE NO.: 119:20733a,20736a
TITLE: Synthetic bactericidal peptide based on CAP37: A
37-kDa human neutrophil granule-associated cationic
antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel,
John K.
CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1993), 90(10),
4733-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 149315-20-8 149383-15-3 149383-16-4
149383-22-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil
granules of humans in relation to)

RN 149315-20-8 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-
arginyl-L-prolyl-L-arginyl-L-glutamyl-L-phenylalanyl-L-prolyl-L-
phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutamyl-L-
asparaginyl-L-glutamylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-
cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-
arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-
seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26-42)-disulfide (9CI)
(CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutamylglycyl-L-arginyl-L-histidyl-L-
phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic
(7-23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

RN 149383-16-4 CAPLUS

CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-
cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-
L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-
L-histidyl-L-cysteinyl-L-valyl-, cyclic (7-23)-disulfide (9CI) (CA
INDEX NAME)

SEQ


1 LRGGHFCGAT LIAPNFVMSA AHCVA



Absolute stereochemistry.

PAGE 1-B




PAGE 2-A





PAGE 3-A



PAGE 3-B



RN 149383-22-2 CAPLUS

CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3-19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> 111

L20 3 L11

=> 112

L21 3 L12

=> 113

L22 23 L13

=> 114

L23 3 L14

=> 119 and 120

L24 2 L19 AND L20

=> 119 and 121

L25 2 L19 AND L21

=> 119 and 122
L26 17 L19 AND L22

=>

=>

=> 119 and 123
L27 2 L19 AND L23

=> 124 or 125 or 127
L28 4 L24 OR L25 OR L27

=> d ibib 124 1-2

L24 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:210198 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 132:218021
TITLE: Cloning and cDNA and deduced amino acid sequences of
31 human secreted proteins
INVENTOR(S): Ruben, Steven M.; Rosen, Craig A.; Duan, Roxanne D.;
Shi, Yanggu; Lafleur, David W.; Young, Paul E.; Ni,
Jian; Komatsoulis, George; Endress, Gregory A.;
Soppet, Daniel R.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; et al.
SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017222	A1	20000330	WO 1999-US22012	19990922 <--
W:			AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW	
RW:			GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2344100	A1	20000330	CA 1999-2344100	19990922 <--
AU 9959288	A	20000410	AU 1999-59288	19990922 <--
EP 1115735	A1	20010718	EP 1999-946997	19990922 <--
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	
JP 2002526059	T	20020820	JP 2000-574130	19990922 <--
US 20020076705	A1	20020620	US 2001-820893	20010330 <--
US 20040048294	A1	20040311	US 2003-607565	20030627 <--
PRIORITY APPLN. INFO.:			US 1998-101546P	P 19980923 <--
			US 1998-102895P	P 19981002 <--
			WO 1999-US22012	W 19990922 <--
			US 2000-531119	B1 20000320 <--
			US 2001-820893	B1 20010330 <--

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 119:115274
ORIGINAL REFERENCE NO.: 119:20733a,20736a
TITLE: Synthetic bactericidal peptide based on CAP37: A
37-kDa human neutrophil granule-associated cationic
antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel,
John K.
CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1993), 90(10),
4733-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d ibib l24 1-2 hitseq

L24 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:210198 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 132:218021
TITLE: Cloning and cDNA and deduced amino acid sequences of
31 human secreted proteins
INVENTOR(S): Ruben, Steven M.; Rosen, Craig A.; Duan, Roxanne D.;
Shi, Yanggu; Lafleur, David W.; Young, Paul E.; Ni,
Jian; Komatsoulis, George; Endress, Gregory A.;
Soppet, Daniel R.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; et al.
SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017222	A1	20000330	WO 1999-US22012	19990922 <--
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2344100	A1	20000330	CA 1999-2344100	19990922 <--
AU 9959288	A	20000410	AU 1999-59288	19990922 <--
EP 1115735	A1	20010718	EP 1999-946997	19990922 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			

JP 2002526059	T	20020820	JP 2000-574130	19990922 <--
US 20020076705	A1	20020620	US 2001-820893	20010330 <--
US 20040048294	A1	20040311	US 2003-607565	20030627 <--
PRIORITY APPLN. INFO.:			US 1998-101546P	P 19980923 <--
			US 1998-102895P	P 19981002 <--
			WO 1999-US22012	W 19990922 <--
			US 2000-531119	B1 20000320 <--
			US 2001-820893	B1 20010330 <--

IT **261164-15-2**

RL: PRP (Properties)

(unclaimed sequence; cloning and cDNA and deduced amino acid sequences of 31 human secreted proteins)


RN 261164-15-2 CAPLUS

CN L-Tryptophan, L-threonyl-L-cysteinyglycylglycyl-L-seryl-L-valyl-L-leucyl-L-alanyl-L-prolyl-L-arginyl-L-tryptophyl-L-valyl-L-valyl-L-threonyl-L-alanyl-L-alanyl-L-histidyl-L-cysteiny-L-methionyl-L-histidyl-L-seryl-L-phenylalanyl-L-arginyl-L-leucyl-L-alanyl-L-arginyl-L-leucyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)



SEQ 1 TCGGSVLAPR WVVTAAHCMH SFRLARLSSW

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C




PAGE 2-A




PAGE 2-B



PAGE 2-C





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 119:115274

ORIGINAL REFERENCE NO.: 119:20733a,20736a

TITLE: Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes

AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel, John K.

CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1993), 90(10), 4733-7

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 149315-20-8 149383-15-3 149383-16-4
149383-22-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)

RN 149315-20-8 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26-42)-disulfide (9CI)
(CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


RN 149383-16-4 CAPLUS




CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-cysteinyglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-L-asparaginy-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-L-histidyl-L-cysteiny-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 LRGGHFCGAT LIAPNFVMSA AHQVA

Absolute stereochemistry.

PAGE 1-B





RN 149383-22-2 CAPLUS
 CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3-19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d ibib 125 1-2 hitseq

L25 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:20444 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 140:110119

TITLE: Mammalian EPO mimetic CH1 deleted mimetibodies,
compositions, methods and uses for diagnosis and
therapy of human diseases

INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John;
Scallion, Bernard J.; Nesspor, Thomas C.; Kutoloski,
Karen A.

PATENT ASSIGNEE(S): Centocor, Inc., USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002424	A2	20040108	WO 2003-US20495	20030630 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490411	A1	20040108	CA 2003-2490411	20030630 <--
AU 2003256336	A1	20040119	AU 2003-256336	20030630 <--
BR 2003012276	A	20050426	BR 2003-12276	20030630 <--
US 20050191301	A1	20050901	US 2003-609783	20030630
US 7241733	B2	20070710		
EP 1575499	A2	20050921	EP 2003-762210	20030630 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005536992	T	20051208	JP 2004-518080	20030630 <--
CN 1735433	A	20060215	CN 2003-820110	20030630 <--
IN 2004KN01988	A	20060707	IN 2004-KN1988	20041224 <--
MX 2005PA00202	A	20050930	MX 2005-PA202	20050103 <--
PRIORITY APPLN. INFO.:			US 2002-392431P	P 20020628 <--
			US 2002-412144P	P 20020919
			WO 2003-US20495	W 20030630

IT 645406-06-0

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(amino acid sequence, mimetibody comprising; mammalian EPO mimetic CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)


RN 645406-06-0 CAPLUS




CN L-Alanine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFA

Absolute stereochemistry.

PAGE 1-A







L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 119:115274

ORIGINAL REFERENCE NO.: 119:20733a,20736a

TITLE: Synthetic bactericidal peptide based on CAP37: A
37-kDa human neutrophil granule-associated cationic
antimicrobial protein chemotactic for monocytes

AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel,
John K.

CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA

SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1993), 90(10),
4733-7

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 149315-20-8 149383-15-3 149383-16-4
149383-22-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)

RN 149315-20-8 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26→42)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ



RN 149383-16-4 CAPLUS

CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)


SEQ 1 LRGGHFCGAT LIAPNFVMSA AHCVA

Absolute stereochemistry.






PAGE 3-A



PAGE 3-B



RN 149383-22-2 CAPLUS
 CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3-19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d ibib 127 1-2 hitseq

L27 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:8914 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 126:56203
 ORIGINAL REFERENCE NO.: 126:10991a,10994a
 TITLE: Isolation and characterization of a peptide from funnel web spider (Agelenopsis aperta) venom
 INVENTOR(S): Yomo, Yasushi; Kuwata, Manabu; Teramoto, Tetsuyuki; Niitome, Tetsuhiro; Sawada, Kohei; Nishizawa, Yukio
 PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08253499	A	19961001	JP 1994-328130	19941228 <--
PRIORITY APPLN. INFO.:			JP 1994-328130	19941228 <--

IT 184786-10-5P

RL: PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; isolation and characterization of a peptide from funnel web spider (*Agelenopsis aperta*) venom)

RN 184786-10-5 CAPLUS

CN Protein (*Agelenopsis aperta* venom agatoxin-like) (9CI) (CA INDEX NAME)

NTE multichain

SEQ 1 IVGGKTAKFG DYPWMVSIQQ KNKKGTFDHI CGGAIINVNW ILTAAHCFDQ
51 PIVKSDYRAY VGLRSILHTK ENTVQRLELS KIVLHPGYKP KKDPDDIALI
101 KVAKPIVIGN YANGICVPKG VTNPEGNATV IGWGKISSGG KQVNTLQEV
151 IPIIPWKKCK EIYGDEFSEF EYSQITPYMI CAGAEKGDSC QADSGGPLFQ
201 IDANGVATLI GTVANGADCG YKHYPGVYMK VSSYTNWMSK NMV

1 VEVATVKNCG KKLLATPR

L27 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 119:115274

ORIGINAL REFERENCE NO.: 119:20733a,20736a

TITLE: Synthetic bactericidal peptide based on CAP37: A
37-kDa human neutrophil granule-associated cationic
antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel,
John K.

CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA

SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1993), 90(10),
4733-7

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 149315-20-8 149383-15-3 149383-16-4

149383-22-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)

RN 149315-20-8 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26+42)-disulfide (9CI)
(CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS

CN L-Glutamine, L-asparaginyL-L-glutaminyLglycyl-L-arginyL-L-histidyl-L-phenylalanyL-L-cysteinyLglycylglycyl-L-alanyL-L-leucyl-L-isoleucyl-L-histidyl-L-alanyL-L-arginyL-L-phenylalanyL-L-valyl-L-methionyl-L-threonyL-L-alanyL-L-alanyL-L-seryL-L-cysteinyL-L-phenylalanyL-, cyclic (7-23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


RN 149383-16-4 CAPLUS



CN L-Alanine, L-leucyl-L-arginyLglycylglycyl-L-histidyl-L-phenylalanyL-L-cysteinyLglycyl-L-alanyL-L-threonyL-L-leucyl-L-isoleucyl-L-alanyL-L-prolyL-L-asparaginyL-L-phenylalanyL-L-valyl-L-methionyl-L-seryL-L-alanyL-L-alanyL-L-histidyl-L-cysteinyL-L-valyl-, cyclic (7-23)-disulfide (9CI) (CA INDEX NAME)






SEQ 1 LRGGHFCGAT LIAPNFVMSA AHCVA

Absolute stereochemistry.

PAGE 1-B







RN 149383-22-2 CAPLUS
 CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3-19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d ibib 126 1-2 hitseq

L26 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:20438 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 140:110118

TITLE: Mammalian CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases

INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallion, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.

PATENT ASSIGNEE(S): Centocor, Inc., USA

SOURCE: PCT Int. Appl., 129 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002417	A2	20040108	WO 2003-US20347	20030627 <--
WO 2004002417	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490409	A1	20040108	CA 2003-2490409	20030627 <--
AU 2003280130	A1	20040119	AU 2003-280130	20030627 <--
EP 1545608	A2	20050629	EP 2003-742272	20030627 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006504406	T	20060209	JP 2004-517981	20030627 <--
PRIORITY APPLN. INFO.:			US 2002-392431P	P 20020628 <--
			WO 2003-US20347	W 20030627

IT **151679-59-3**

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence, mimetibody comprising; mammalian CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyL-L-glutaminyLglycyl-L-arginyL-L-histidyl-L-




phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A













L26 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:874784 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 139:358727
 TITLE: CAP37/CAP37 peptides for use as bacteriostatics for
 contact lens and corneal transplants and for treatment
 of ocular infections
 INVENTOR(S): Pereira, Heloise Anne; Chodosh, James; Callegan,
 Michelle C.
 PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma,
 USA
 SOURCE: U.S. Pat. Appl. Publ., 31 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------





REFERENCE COUNT:

33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib 126 3-17 hitseq

L26 ANSWER 3 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:816705 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 135:366701
TITLE: Fc-domain-modified peptides as therapeutic agents
INVENTOR(S): Feige, Ulrich; Liu, Chuan-Fa; Cheetham, Janet C.;
Boone, Thomas Charles; Gudas, Jean Marie
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083525	A2	20011108	WO 2001-US14310	20010502 <--
WO 2001083525	A3	20020718		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2407956	A1	20011108	CA 2001-2407956	20010502 <--
EP 1278778	A2	20030129	EP 2001-932951	20010502 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003533187	T	20031111	JP 2001-580949	20010502 <--
AU 2001259432	B2	20050421	AU 2001-259432	20010502 <--
MX 2002PA10787	A	20030714	MX 2002-PA10787	20021101 <--
US 20050123548	A1	20050609	US 2003-645784	20030818 <--
US 20040077022	A1	20040422	US 2003-666696	20030919 <--
US 20060234307	A1	20061019	US 2006-472070	20060620 <--
PRIORITY APPLN. INFO.:			US 2000-563286	A 20000503 <--
			US 1998-105371P	P 19981023 <--
			US 1999-428082	A2 19991022 <--
			WO 2001-US14310	W 20010502 <--
			US 2003-666696	A1 20030919

IT 151679-59-3

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Fc-domain-modified peptides as therapeutic agents)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)

SEQ

1 NQGRHF CGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





CC(=O)CCNC(=O)CCNC(=O)C(R)SNC(=O)C(S[C@H](Cc1ccccc1)N)C(=O)N[C@H](Cc2c[nH]cn2)C(=O)SC(=O)N[C@@H](Cc3c[nH]cn3)C(=O)NCCNC(=O)N

The diagram shows the chemical structure of the cyclic dimer of L-cysteine. It consists of two L-cysteine units linked by disulfide bonds. Each unit is represented as a five-membered ring containing a nitrogen atom (part of an amide group) and a sulfur atom (part of a disulfide bridge). The amino group (NH₂) of each unit is shown with a wedge bond, indicating its stereochemistry. The structure is symmetrical, with the two units connected by two disulfide bonds, forming a closed ring.


L26 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:782060 CAPLUS <<LOGINID::20081208>>
 Correction of: 1997:601254
 DOCUMENT NUMBER: 135:287507
 Correction of: 127:306552
 TITLE: Interaction of a synthetic peptide based on the
 neutrophil-derived antimicrobial protein CAP37 with
 dipalmitoyl-phosphatidylcholine membranes
 AUTHOR(S): Lambros, Maria Polikandritou; Sheu, Eric; Lin, J. S.;
 Pereira, H. Anne
 CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health
 Sciences Center, Oklahoma City, OK, USA
 SOURCE: Biochimica et Biophysica Acta, Biomembranes (
 1997), 1329(2), 285-290 .
 CODEN: BBBMBS; ISSN: 0005-2736
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT **151679-59-3P**
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (interaction of a synthetic peptide based on the neutrophil-derived
 antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine
 membranes)
 RN 151679-59-3 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-
 phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
 histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
 L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 2000:824291 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 134:21425
 TITLE: Protection of endogenous therapeutic peptides from
 peptidase activity through conjugation to blood
 components
 INVENTOR(S): Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter
 G.; Holmes, Darren L.; Thibaudeau, Karen
 PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
 SOURCE: PCT Int. Appl., 733 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069900	A2	20001123	WO 2000-US13576	20000517 <--
WO 2000069900	A3	20010215		
WO 2000069900	A9	20020704		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373252	A1	20001123	CA 2000-2373252	20000517 <--
CA 2373252	C	20070807		
CA 2373680	A1	20001123	CA 2000-2373680	20000517 <--
CA 2373680	C	20080729		
CA 2499211	A1	20001123	CA 2000-2499211	20000517 <--
CA 2501421	A1	20001123	CA 2000-2501421	20000517 <--
CA 2505617	A1	20001123	CA 2000-2505617	20000517 <--
CA 2623458	A1	20001123	CA 2000-2623458	20000517 <--
WO 2000070665	A2	20001123	WO 2000-IB763	20000517 <--
WO 2000070665	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1105409	A2	20010613	EP 2000-936023	20000517 <--
EP 1105409	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EP 1171582	A2	20020116	EP 2000-929748	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1264840	A1	20021211	EP 2002-14617	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003500341	T	20030107	JP 2000-619018	20000517 <--
JP 2003508350	T	20030304	JP 2000-618316	20000517 <--
AU 765753	B2	20030925	AU 2000-51393	20000517 <--
EP 1591453	A1	20051102	EP 2005-105384	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
CN 1698881	A	20051123	CN 2005-10005990	20000517 <--
EP 1598365	A1	20051123	EP 2005-105387	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1623994	A2	20060208	EP 2005-108328	20000517 <--
EP 1623994	A3	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 318835	T	20060315	AT 2000-936023	20000517 <--
PT 1105409	T	20060731	PT 2000-936023	20000517 <--
ES 2257298	T3	20060801	ES 2000-936023	20000517 <--
CN 101289500	A	20081022	CN 2008-10091504	20000517 <--
US 6849714	B1	20050201	US 2000-623548	20000905 <--
US 6514500	B1	20030204	US 2000-657332	20000907 <--
US 7090851	B1	20060815	US 2000-657336	20000907 <--
US 7144854	B1	20061205	US 2000-657431	20000907 <--
ZA 2001006676	A	20020719	ZA 2001-6676	20010814 <--
ZA 2001009110	A	20020613	ZA 2001-9110	20011105 <--
US 20030108567	A1	20030612	US 2002-287892	20021104 <--
US 6821949	B2	20041123		
US 20030108568	A1	20030612	US 2002-288340	20021104 <--
US 6887849	B2	20050503		
US 20040127398	A1	20040701	US 2003-722733	20031125 <--
US 20040138100	A1	20040715	US 2003-723099	20031125 <--
US 20050176641	A1	20050811	US 2005-40810	20050121 <--
US 20050176643	A1	20050811	US 2005-67556	20050225 <--
JP 2005263807	A	20050929	JP 2005-115175	20050412 <--
JP 2005239736	A	20050908	JP 2005-140407	20050512 <--
JP 2005255689	A	20050922	JP 2005-151458	20050524 <--
JP 4116016	B2	20080709		
US 20060009377	A1	20060112	US 2005-170967	20050629 <--
US 20060058235	A1	20060316	US 2005-215967	20050830 <--
JP 2006151986	A	20060615	JP 2005-361126	20051214 <--
US 20060135426	A1	20060622	US 2005-304446	20051214 <--
US 20060135428	A1	20060622	US 2006-350703	20060208 <--
US 20080194486	A1	20080814	US 2007-923222	20071024 <--
US 20080199532	A1	20080821	US 2007-926843	20071029 <--
JP 2008101021	A	20080501	JP 2007-325307	20071217 <--
JP 2008110986	A	20080515	JP 2008-8554	20080117 <--
JP 2008150384	A	20080703	JP 2008-8555	20080117 <--
PRIORITY APPLN. INFO.:			US 1999-134406P	P 19990517 <--
			US 1999-153406P	P 19990910 <--
			US 1999-159783P	P 19991015 <--
			US 1999-134406	A 19990517 <--
			US 1999-153406	A 19990910 <--
			US 1999-159783	A 19991015 <--
			CA 2000-2363712	A3 20000517 <--
			CA 2000-2373680	A3 20000517 <--
			CN 2000-807671	A3 20000517 <--

EP 2000-932570	A3 20000517 <--
EP 2000-936023	A3 20000517 <--
JP 2000-618316	A3 20000517 <--
JP 2000-618318	A3 20000517 <--
JP 2000-618327	A3 20000517 <--
JP 2000-619018	A3 20000517 <--
WO 2000-IB763	W 20000517 <--
WO 2000-US13576	W 20000517 <--
US 2000-623543	A1 20000905 <--
US 2000-623548	A1 20000905 <--
US 2000-657276	A2 20000907 <--
US 2000-657332	A3 20000907 <--
US 2000-657431	A1 20000907 <--
US 2002-400199P	P 20020731 <--
US 2002-400413P	P 20020731 <--
US 2002-288340	A1 20021104
WO 2003-CA1097	W 20030729
US 2003-471348	A1 20030908
US 2003-722733	A1 20031125
US 2005-40810	A2 20050121
US 2005-67556	A1 20050225
US 2005-170967	A1 20050629
US 2005-215967	A1 20050830

IT 151679-59-3

RL: PRP (Properties)



(unclaimed sequence; protection of endogenous therapeutic peptides from
peptidase activity through conjugation to blood components)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyL-L-glutaminyLglycyl-L-arginyL-L-histidyl-L-
phenylalanyl-L-cysteinyLglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
L-alanyl-L-alanyl-L-seryl-L-cysteinyL-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 2000:725850 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 133:295374
 TITLE: Lipopolysaccharide immunoassay and test device
 INVENTOR(S): Badley, Robert Andrew; Hughes, Glen; Zak, Krzysztof Wojciech
 PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever N. V.; Hindustan Lever Limited
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060354	A1	20001012	WO 2000-EP2869	20000403 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368975	A1	20001012	CA 2000-2368975	20000403 <--
EP 1166113	A1	20020102	EP 2000-926787	20000403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541457	T	20021203	JP 2000-609793	20000403 <--
AU 763916	B2	20030807	AU 2000-45415	20000403 <--
US 20030054422	A1	20030320	US 2002-131433	20020423 <--
PRIORITY APPLN. INFO.:			EP 1999-302711	A 19990407 <--
			WO 2000-EP2869	W 20000403 <--
			US 2000-545180	A3 20000407 <--

IT **151679-59-3**

RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
 PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL
 (Biological study); USES (Uses)
 (antibody and lipopolysaccharide binding protein for immunodetection of
 lipopolysaccharide and clin. diagnosis of gram-neg. bacterial
 infection)


RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginy-L-glutaminyglycyl-L-arginyl-L-histidyl-L-
 phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
 histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
 L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ




Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:587063 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 133:187935
 TITLE: Antibacterial CAP37 peptides and therapeutic use thereof
 INVENTOR(S): Pereira, H. Anne
 PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA
 SOURCE: U.S., 40 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6107460	A	20000822	US 1999-258934	19990301 <--
US 6514701	B1	20030204	US 2000-619283	20000719 <--
US 20040048792	A1	20040311	US 2002-328125	20021220 <--
US 6730659	B2	20040504		
PRIORITY APPLN. INFO.:			US 1999-258934	A3 19990301 <--
			US 2000-619283	A3 20000719 <--

OTHER SOURCE(S): MARPAT 133:187935

IT 151679-59-3 288855-83-4 288856-01-9
288856-02-0 288856-03-1 288856-10-0
288856-11-1 288856-12-2 288856-14-4
288856-15-5 288856-16-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibacterial CAP37 peptides and therapeutic use thereof)


RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 288855-83-4 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHFCCGA LIHARFVMTA AHCFQ



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B










RN 288856-01-9 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCAGA LIHARFVMTA ASCFQ

Absolute stereochemistry.






RN 288856-02-0 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-




phenylalanyl-L-cysteinylglycyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 NQGRHFCGAA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A










RN 288856-03-1 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCAAA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 288856-10-0 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-threonyl-L-cysteiny-L-phenylalanyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ATCFQ



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 288856-11-1 CAPLUS




CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-leucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFLMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A












RN 288856-12-2 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFIMTA ASCFQ

Absolute stereochemistry.






RN 288856-14-4 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-

tyrosyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHYCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A








— SMe



RN 288856-15-5 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-tyrosyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCCGA LIHARYVM TA ASCFQ

Absolute stereochemistry.






RN 288856-16-6 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-tyrosyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ASCYQ



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:291095 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 132:329919
 TITLE: Modified peptides containing an antibody Fc domain as therapeutic agents
 INVENTOR(S): Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 608 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024782	A2	20000504	WO 1999-US25044	19991025 <--
WO 2000024782	A3	20020606		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6660843	B1	20031209	US 1999-428082	19991022 <--
CA 2347131	A1	20000504	CA 1999-2347131	19991025 <--
EP 1144454	A2	20011017	EP 1999-971003	19991025 <--
EP 1144454	A3	20020911		
EP 1144454	B1	20071212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK				
CN 1331701	A	20020116	CN 1999-814727	19991025 <--
CN 1310948	C	20070418		
BR 9914708	A	20020716	BR 1999-14708	19991025 <--
HU 2002003506	A2	20030228	HU 2002-3506	19991025 <--
JP 2003512011	T	20030402	JP 2000-578351	19991025 <--
AU 767725	B2	20031120	AU 2000-12322	19991025 <--
NZ 510888	A	20040130	NZ 1999-510888	19991025 <--
NZ 528882	A	20050624	NZ 1999-528882	19991025 <--
CN 1721447	A	20060118	CN 2005-10082591	19991025 <--
CN 1746189	A	20060315	CN 2005-10083696	19991025 <--
CN 100384880	C	20080430		
CN 1746190	A	20060315	CN 2005-10083697	19991025 <--
CN 1781945	A	20060607	CN 2005-10081495	19991025 <--
CN 100384879	C	20080430		
CN 1781946	A	20060607	CN 2005-10081496	19991025 <--
CN 1781947	A	20060607	CN 2005-10081497	19991025 <--
CN 1908014	A	20070207	CN 2005-10081952	19991025 <--
AT 380828	T	20071215	AT 1999-971003	19991025 <--
ES 2299278	T3	20080516	ES 1999-971003	19991025 <--
ZA 2001002753	A	20020611	ZA 2001-2753	20010404 <--
MX 2001PA03873	A	20031014	MX 2001-PA3873	20010417 <--
NO 2001001963	A	20010621	NO 2001-1963	20010420 <--
BG 105461	A	20030430	BG 2001-105461	20010424 <--
HK 1042097	A1	20080403	HK 2002-102701	20020410 <--
US 20040044188	A1	20040304	US 2003-609217	20030627 <--
US 7166707	B2	20070123		
US 20040053845	A1	20040318	US 2003-632388	20030731 <--
US 7189827	B2	20070313		
US 20040071712	A1	20040415	US 2003-645761	20030818 <--
US 20050123548	A1	20050609	US 2003-645784	20030818 <--
US 20040057953	A1	20040325	US 2003-651723	20030829 <--
US 7169905	B2	20070130		
US 20040087778	A1	20040506	US 2003-653048	20030829 <--
US 7186810	B2	20070306		
US 20040077022	A1	20040422	US 2003-666696	20030919 <--
AU 2004200687	A1	20040318	AU 2004-200687	20040220 <--
AU 2004200687	B2	20070510		
AU 2004200690	A1	20040318	AU 2004-200690	20040220 <--
AU 2004200690	B2	20070510		
AU 2004200691	A1	20040318	AU 2004-200691	20040220 <--
AU 2004200691	B2	20070329		

US 20060234307	A1	20061019	US 2006-472070	20060620 <--
JP 2007084555	A	20070405	JP 2006-288325	20061024 <--
JP 2007084556	A	20070405	JP 2006-288346	20061024 <--
JP 2007084557	A	20070405	JP 2006-288383	20061024 <--
JP 2007084558	A	20070405	JP 2006-288397	20061024 <--
JP 2007091746	A	20070412	JP 2006-288324	20061024 <--
JP 2007091747	A	20070412	JP 2006-288347	20061024 <--
JP 2007089586	A	20070412	JP 2006-288382	20061024 <--
JP 2007105044	A	20070426	JP 2006-288398	20061024 <--
US 20070049532	A1	20070301	US 2006-591002	20061031 <--
KR 2007050977	A	20070516	KR 2007-706958	20070327 <--
KR 2007050978	A	20070516	KR 2007-706961	20070327 <--
PRIORITY APPLN. INFO.:			US 1998-105371P	P 19981023 <--
			US 1999-428082	A 19991022 <--
			AU 2000-12322	A3 19991025 <--
			CN 1999-814727	A3 19991025 <--
			JP 2000-578351	A3 19991025 <--
			WO 1999-US25044	W 19991025 <--
			US 2000-563286	A1 20000503 <--
			KR 2001-704982	A3 20010420 <--
			US 2003-645761	A3 20030818
			US 2003-666696	A1 20030919
			AU 2004-200687	A 20040220



IT **151679-59-3D**, fusion protein with IgG1 Fc domain
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CAP37 mimetic/LPS binding; modified peptides containing an antibody Fc domain as therapeutic agents)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyL-L-glutaminyLglycyl-L-arginyL-L-histidyL-L-phenylalanyl-L-cysteinyLglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyL-L-alanyl-L-arginyL-L-phenylalanyl-L-valyl-L-methionyl-L-threonyL-L-alanyl-L-alanyl-L-seryl-L-cysteinyL-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCCGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 1997:601254 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:306552
ORIGINAL REFERENCE NO.: 127:59951a
TITLE: Interaction of a synthetic peptide based on the
neutrophil-derived antimicrobial protein CAP37 with
dipalmitoyl-phosphatidylcholine membranes
AUTHOR(S): Polikandritou Lambros, Maria; Sheu, Eric; Lin, J. S.;
Pereira, H. Anne
CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health
Sciences Center, Oklahoma City, OK, USA
SOURCE: Biochimica et Biophysica Acta, Biomembranes (
1997), 1329(2), 285-290
CODEN: BBBMBS; ISSN: 0005-2736
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 151679-59-3P



RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(interaction of a synthetic peptide based on the neutrophil-derived
antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine
membranes)




RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyL-L-glutaminyLglycyl-L-arginyL-L-histidyl-L-
phenylalanyl-L-cysteinyLglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
histidyl-L-alanyl-L-arginyL-L-phenylalanyl-L-valyl-L-methionyl-L-threonyL-
L-alanyl-L-alanyl-L-seryl-L-cysteinyL-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.





REFERENCE COUNT:

14

THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:408609 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 127:148252

ORIGINAL REFERENCE NO.: 127:28629a

TITLE: A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats

AUTHOR(S): Brackett, Daniel J.; Lerner, Megan R.; Lacquement, Melissa A.; He, Rong; Pereira, H. Anne

CORPORATE SOURCE: Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73190, USA

SOURCE: Infection and Immunity (1997), 65(7), 2803-2811

CODEN: INFIBR; ISSN: 0019-9567

PUBLISHER: American Society for Microbiology

DOCUMENT TYPE: Journal

LANGUAGE: English

IT 151679-59-3



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (synthetic lipopolysaccharide-binding peptide based on neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT:

75

THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:344807 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 127:13456
 ORIGINAL REFERENCE NO.: 127:2623a,2626a
 TITLE: Method and composition for the treatment of septic shock
 INVENTOR(S): Pereira, Heloise A.
 PATENT ASSIGNEE(S): University of Oklahoma, USA
 SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,607,916.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:			US 1989-375739	B2 19890705 <--
			US 1990-543151	B2 19900625 <--
			US 1992-855417	A1 19920319 <--
			US 1992-969931	A2 19921030 <--
			US 1994-235399	A2 19940429 <--
			US 1992-939931	A2 19921030 <--
			US 1995-482328	A1 19950607 <--
			US 1997-840519	A1 19970421 <--

IT 151679-59-3



RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
 (method and composition for the treatment of septic shock)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyL-L-glutaminyLglycyl-L-arginyL-L-histidyL-L-phenylalanyL-L-cysteinyLglycylglycyl-L-alanyL-L-leucyL-L-isoleucyL-L-histidyL-L-alanyL-L-arginyL-L-phenylalanyL-L-valyL-L-methionyL-L-threonyL-L-alanyL-L-alanyL-L-seryL-L-cysteinyL-L-phenylalanyL- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 1997:204303 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 126:207540
 ORIGINAL REFERENCE NO.: 126:40001a
 TITLE: Method and composition using
 lipopolysaccharide-binding peptide derived from CAP37
 protein for the treatment of septic shock
 INVENTOR(S): Pereira, Heloise A.; Brackett, Daniel J.; Lerner,
 Megan R.
 PATENT ASSIGNEE(S): Board of Regents of the University of Oklahoma, USA
 SOURCE: U.S., 19 pp., Cont.-in-part of U.S.5,458,874.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
US 5650392	A	19970722	US 1995-455485	19950531 <--
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:			US 1989-375739	B2 19890705 <--
			US 1990-543151	B2 19900625 <--
			US 1992-855417	A1 19920319 <--
			US 1992-969931	A2 19921030 <--
			US 1992-939931	A2 19921030 <--
			US 1994-235399	A3 19940429 <--
			US 1995-482328	A1 19950607 <--
			US 1997-840519	A1 19970421 <--

IT 151679-59-3




RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (lipopolysaccharide-binding peptide derived from CAP37 protein for the
 treatment of septic shock)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-
 phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
 histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
 L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 1996:137923 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 124:315067
 ORIGINAL REFERENCE NO.: 124:58442h,58443a
 TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
 INVENTOR(S): Pereira, Heloise A.; Spitznagel, John K.
 PATENT ASSIGNEE(S): Emory University, USA
 SOURCE: U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 543,151, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9348089	A	19931021	AU 1993-48089	19930319 <--
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5650392	A	19970722	US 1995-455485	19950531 <--
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:				
			US 1989-375739	B2 19890705 <--
			US 1990-543151	B2 19900625 <--
			US 1992-855417	A1 19920319 <--
			US 1992-939931	A2 19921030 <--
			US 1992-969931	A2 19921030 <--
			WO 1993-US2580	A 19930319 <--
			US 1994-235399	A3 19940429 <--
			US 1995-482328	A1 19950607 <--
			US 1997-840519	A1 19970421 <--

IT **151679-59-3P**

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (chemotactic/antibiotic/lipopolysaccharide-binding peptide fragments of CAP37 for treating wounds, tumors, and infections)


RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)


SEQ 1 NQGRHFCCGA LIHARFVMTA ASCFQ




Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





ACCESSION NUMBER: 1996:32761 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 124:114140
 ORIGINAL REFERENCE NO.: 124:21195a,21198a
 TITLE: A cationic antimicrobial peptide enhances the infectivity of *Coxiella burnetii*
 AUTHOR(S): Aragón, A. S.; Pereira, H. A.; Baca, O. G.
 CORPORATE SOURCE: Biology Department, University of New Mexico, Albuquerque, NM, 8713-1091, USA
 SOURCE: Acta Virologica (English Edition) (1995), 39(4), 223-6
 CODEN: AVIRA2; ISSN: 0001-723X
 PUBLISHER: Slovak Academic Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English

IT 151679-59-3

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
 (CAP3720-44 (a synthetic peptide based on the 37-Kd human neutrophil granule-associated cationic antimicrobial protein, CAP37) enhances the infectivity of *Coxiella burnetii*)


RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A





PAGE 1-B



PAGE 2-A





L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:17399 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 124:84820
 ORIGINAL REFERENCE NO.: 124:15949a,15952a
 TITLE: Sperm immobilizing activity of a synthetic bioactive peptide 20-44 of 37-kDa cationic antimicrobial protein (CAP37) of human neutrophils
 AUTHOR(S): D'Cruz, Osmond J.; Pereira, H. Anne; Haas, Gilbert G. Jr.
 CORPORATE SOURCE: Health Sciences Center, University Oklahoma, Oklahoma City, OK, 73190, USA
 SOURCE: Journal of Andrology (1995), 16(5), 432-40
 CODEN: JOAND3; ISSN: 0196-3635
 PUBLISHER: American Society of Andrology
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 151679-59-3
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)

(sperm immobilization by peptide 20-44 fragment of CAP37 of human neutrophils)


RN 151679-59-3 CAPLUS



CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A







L26 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:563 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 120:563
 ORIGINAL REFERENCE NO.: 120:135a,138a
 TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
 INVENTOR(S): Pereira, Heloise Anne; Spitznagel, John K.
 PATENT ASSIGNEE(S): Emory University, USA
 SOURCE: PCT Int. Appl., 108 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--

W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
US 5484885 A 19960116 US 1992-855417 19920319 <--
AU 9348089 A 19931021 AU 1993-48089 19930319 <--
PRIORITY APPLN. INFO.: US 1992-855417 A 19920319 <--
US 1989-375739 B2 19890705 <--
US 1990-543151 B2 19900625 <--
WO 1993-US2580 A 19930319 <--

IT 151705-32-7 151769-18-5 152699-65-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of)


RN 151705-32-7 CAPLUS



CN L-Glutamine, L-asparaginyl-L-glutaminyl-L-glutaminyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 NQQRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A







RN 151769-18-5 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ


RN 152699-65-5 CAPLUS

CN L-Glutamine, L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 FCGGALIHAR FVMTAASCFQ


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



IT **151679-59-3**

RL: BIOL (Biological study)

(of chemotactic protein, of neutrophil, bactericidal and
lipopolysaccharide-binding activity of)


RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-
phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)



SEQ 1. NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 119:115274
ORIGINAL REFERENCE NO.: 119:20733a,20736a
TITLE: Synthetic bactericidal peptide based on CAP37: A
37-kDa human neutrophil granule-associated cationic
antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel,
John K.
CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Proceedings of the National Academy of Sciences of the
United States of America (1993), 90(10),
4733-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English

IT 149315-20-8 149383-15-3 149383-16-4
149383-22-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil
granules of humans in relation to)

RN 149315-20-8 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-
arginyl-L-prolyl-L-arginyl-L-glutamyl-L-phenylalanyl-L-prolyl-L-
phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutamyl-L-
asparaginyl-L-glutamylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-
cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-
arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-
seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26→42)-disulfide (9CI)
(CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutamylglycyl-L-arginyl-L-histidyl-L-
phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic
(7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

RN 149383-16-4 CAPLUS


CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-
cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-
L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-
L-histidyl-L-cysteinyl-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA
INDEX NAME)



1 LRGGHFCGAT LIAPNFVMSA AHCVA


PAGE 1-B



PAGE 2-A







RN 149383-22-2 CAPLUS

CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3-19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d his ful que sta

'QUE' IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY HISTORY".

=> d his ful

(FILE 'HOME' ENTERED AT 09:00:30 ON 08 DEC 2008)

FILE 'REGISTRY' ENTERED AT 09:00:39 ON 08 DEC 2008

L1 0 SEA PLU=ON [RK] [ARNQGHILKMFPSTWVY]C[AGS] [TAGS] [HILMFPTVWY] [HILMFPTVWY] [AGSHILMFPTVWYNQ] [ARNQGHILKMFPSTWVY] [RKHILMFPTVWYNQ] [HILMFPTVWY] [HILMFPTVWY] [HILMFPTVWY] [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP

L2 4577 SEA PLU=ON [ANRQGHILKMFPSTWYV]C([AGS]){2} [TAGS] ([HILMFPTVWY]){2} [AGSHILMFPTVWY]ANRQGHILKMFPSTWYV [ANRQGHILKMFPSTWYV] [RKHILMFPTVWYNQ] ([HILMFPTVWY]){3} [SHILMFPTVWY] [AGS] [AGSHILMFPTVWY] [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP

L3 32 SEA PLU=ON L2 AND SQL<=29

L4 37 SEA PLU=ON ^.{1-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RK HILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS].[AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY].{1-5}/SQSP

L5 35 SEA PLU=ON ^.{2-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RK HILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY].{1-5}/SQSP

L6 1428 SEA PLU=ON [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][PRQ][RK HILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP

L7 277 SEA PLU=ON [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RK HILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY][RA]/SQSP

L8 251 SEA PLU=ON [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RK HILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]Q/SQSP

L9 1447 SEA PLU=ON [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][NQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP

L10 35 SEA PLU=ON L2 AND SQL=<44

L11 12 SEA PLU=ON L10 AND L6

L12 11 SEA PLU=ON L10 AND L7

L13 19 SEA PLU=ON L10 AND L8

L14 5 SEA PLU=ON L10 AND L9

L15 33 SEA PLU=ON L11 OR L12 OR L13 OR L14

FILE 'CAPLUS' ENTERED AT 09:08:37 ON 08 DEC 2008

L16 26 SEA PLU=ON L15

L17 17 SEA PLU=ON L16 AND PD<=20030814

L18 15 SEA PLU=ON L16 AND PRD<=20030814

L19 20 SEA PLU=ON L16 AND (PD<=20020814 OR PRD<=20020814)
D L19 1-20 IBIB HITSEQ

L20 3 SEA PLU=ON L11

L21 3 SEA PLU=ON L12

L22 23 SEA PLU=ON L13

L23 3 SEA PLU=ON L14

L24 2 SEA PLU=ON L19 AND L20

L25 2 SEA PLU=ON L19 AND L21

L26 17 SEA PLU=ON L19 AND L22

L27 2 SEA PLU=ON L19 AND L23

L28 4 SEA PLU=ON L24 OR L25 OR L27
D IBIB L24 1-2
D IBIB L24 1-2 HITSEQ
D IBIB L25 1-2 HITSEQ
D IBIB L27 1-2 HITSEQ
D IBIB L26 1-2 HITSEQ
D IBIB L26 3-17 HITSEQ

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

DICTIONARY FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE CAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Dec 2008 VOL 149 ISS 24



FILE LAST UPDATED: 7 Dec 2008 (20081207/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> log y



L19 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:20438 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 140:110118
 TITLE: Mammalian CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases
 INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallon, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.
 PATENT ASSIGNEE(S): Centocor, Inc., USA
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2004002417	A2	20040108	WO 2003-US20347	20030627 <--
WO 2004002417	A3	20041104		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2490409	A1	20040108	CA 2003-2490409	20030627 <--
AU 2003280130	A1	20040119	AU 2003-280130	20030627 <--
EP 1545608	A2	20050629	EP 2003-742272	20030627 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2006504406	T	20060209	JP 2004-517981	20030627 <--
PRIORITY APPLN. INFO.:			US 2002-392431P	P 20020628 <--
			WO 2003-US20347	W 20030627

IT **151679-59-3**

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(amino acid sequence, mimetibody comprising; mammalian CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCCGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 2003:874784 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 139:358727
 TITLE: CAP37/CAP37 peptides for use as bacteriostatics for contact lens and corneal transplants and for treatment of ocular infections
 INVENTOR(S): Pereira, Heloise Anne; Chodosh, James; Callegan, Michelle C.
 PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA
 SOURCE: U.S. Pat. Appl. Publ., 31 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030206938	A1	20031106	US 2003-423311	20030425 <--
US 7354900	B2	20080408		
WO 2003092718	A2	20031113	WO 2003-US13146	20030428 <--
WO 2003092718	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003239184	A1	20031117	AU 2003-239184	20030428 <--
EP 1503784	A2	20050209	EP 2003-733902	20030428 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			US 2002-378295P	P 20020503 <--
			WO 2003-US13146	W 20030428

IT **151679-59-3**

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)



(human CAP37 peptide; CAP37/CAP37 peptides for use as bacteriostatics for contact lens and corneal transplants and for treatment of ocular infections)




RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.





REFERENCE COUNT:

33

THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:816705 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 135:366701
 TITLE: Fc-domain-modified peptides as therapeutic agents
 INVENTOR(S): Feige, Ulrich; Liu, Chuan-Fa; Cheetham, Janet C.;
 Boone, Thomas Charles; Gudas, Jean Marie
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 176 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083525	A2	20011108	WO 2001-US14310	20010502 <--
WO 2001083525	A3	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2407956	A1	20011108	CA 2001-2407956	20010502 <--
EP 1278778	A2	20030129	EP 2001-932951	20010502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533187	T	20031111	JP 2001-580949	20010502 <--
AU 2001259432	B2	20050421	AU 2001-259432	20010502 <--
MX 2002PA10787	A	20030714	MX 2002-PA10787	20021101 <--
US 20050123548	A1	20050609	US 2003-645784	20030818 <--
US 20040077022	A1	20040422	US 2003-666696	20030919 <--
US 20060234307	A1	20061019	US 2006-472070	20060620 <--
PRIORITY APPLN. INFO.:			US 2000-563286	A 20000503 <--
			US 1998-105371P	P 19981023 <--
			US 1999-428082	A2 19991022 <--
			WO 2001-US14310	W 20010502 <--
			US 2003-666696	A1 20030919

IT **151679-59-3**
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Fc-domain-modified peptides as therapeutic agents)
 RN 151679-59-3 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B








PAGE 2-C



L19 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:782060 CAPLUS <<LOGINID::20081208>>
 Correction of: 1997:601254
 DOCUMENT NUMBER: 135:287507
 Correction of: 127:306552
 TITLE: Interaction of a synthetic peptide based on the
 neutrophil-derived antimicrobial protein CAP37 with
 dipalmitoyl-phosphatidylcholine membranes
 AUTHOR(S): Lambros, Maria Polikandritou; Sheu, Eric; Lin, J. S.;
 Pereira, H. Anne
 CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health
 Sciences Center, Oklahoma City, OK, USA
 SOURCE: Biochimica et Biophysica Acta, Biomembranes (
 1997), 1329(2), 285-290
 CODEN: BBBMBS; ISSN: 0005-2736
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT **151679-59-3P**
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP
 (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
 (interaction of a synthetic peptide based on the neutrophil-derived
 antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine
 membranes)
 RN 151679-59-3 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-
 phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
 histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
 L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)
 SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.





ACCESSION NUMBER: 2000:824291 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 134:21425
 TITLE: Protection of endogenous therapeutic peptides from
 peptidase activity through conjugation to blood
 components
 INVENTOR(S): Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter
 G.; Holmes, Darren L.; Thibaudeau, Karen
 PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
 SOURCE: PCT Int. Appl., 733 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 5
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069900	A2	20001123	WO 2000-US13576	20000517 <--
WO 2000069900	A3	20010215		
WO 2000069900	A9	20020704		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373252	A1	20001123	CA 2000-2373252	20000517 <--
CA 2373252	C	20070807		
CA 2373680	A1	20001123	CA 2000-2373680	20000517 <--
CA 2373680	C	20080729		
CA 2499211	A1	20001123	CA 2000-2499211	20000517 <--
CA 2501421	A1	20001123	CA 2000-2501421	20000517 <--
CA 2505617	A1	20001123	CA 2000-2505617	20000517 <--
CA 2623458	A1	20001123	CA 2000-2623458	20000517 <--
WO 2000070665	A2	20001123	WO 2000-IB763	20000517 <--
WO 2000070665	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1105409	A2	20010613	EP 2000-936023	20000517 <--
EP 1105409	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EP 1171582	A2	20020116	EP 2000-929748	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1264840	A1	20021211	EP 2002-14617	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003500341	T	20030107	JP 2000-619018	20000517 <--
JP 2003508350	T	20030304	JP 2000-618316	20000517 <--
AU 765753	B2	20030925	AU 2000-51393	20000517 <--
EP 1591453	A1	20051102	EP 2005-105384	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
CN 1698881	A	20051123	CN 2005-10005990	20000517 <--
EP 1598365	A1	20051123	EP 2005-105387	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1623994	A2	20060208	EP 2005-108328	20000517 <--
EP 1623994	A3	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 318835	T	20060315	AT 2000-936023	20000517 <--
PT 1105409	T	20060731	PT 2000-936023	20000517 <--
ES 2257298	T3	20060801	ES 2000-936023	20000517 <--
CN 101289500	A	20081022	CN 2008-10091504	20000517 <--
US 6849714	B1	20050201	US 2000-623548	20000905 <--
US 6514500	B1	20030204	US 2000-657332	20000907 <--
US 7090851	B1	20060815	US 2000-657336	20000907 <--
US 7144854	B1	20061205	US 2000-657431	20000907 <--
ZA 2001006676	A	20020719	ZA 2001-6676	20010814 <--
ZA 2001009110	A	20020613	ZA 2001-9110	20011105 <--
US 20030108567	A1	20030612	US 2002-287892	20021104 <--
US 6821949	B2	20041123		
US 20030108568	A1	20030612	US 2002-288340	20021104 <--
US 6887849	B2	20050503		
US 20040127398	A1	20040701	US 2003-722733	20031125 <--
US 20040138100	A1	20040715	US 2003-723099	20031125 <--
US 20050176641	A1	20050811	US 2005-40810	20050121 <--
US 20050176643	A1	20050811	US 2005-67556	20050225 <--
JP 2005263807	A	20050929	JP 2005-115175	20050412 <--
JP 2005239736	A	20050908	JP 2005-140407	20050512 <--
JP 2005255689	A	20050922	JP 2005-151458	20050524 <--
JP 4116016	B2	20080709		
US 20060009377	A1	20060112	US 2005-170967	20050629 <--
US 20060058235	A1	20060316	US 2005-215967	20050830 <--
JP 2006151986	A	20060615	JP 2005-361126	20051214 <--
US 20060135426	A1	20060622	US 2005-304446	20051214 <--
US 20060135428	A1	20060622	US 2006-350703	20060208 <--
US 20080194486	A1	20080814	US 2007-923222	20071024 <--
US 20080199532	A1	20080821	US 2007-926843	20071029 <--
JP 2008101021	A	20080501	JP 2007-325307	20071217 <--
JP 2008110986	A	20080515	JP 2008-8554	20080117 <--
JP 2008150384	A	20080703	JP 2008-8555	20080117 <--
PRIORITY APPLN. INFO.:			US 1999-134406P	P 19990517 <--
			US 1999-153406P	P 19990910 <--
			US 1999-159783P	P 19991015 <--
			US 1999-134406	A 19990517 <--
			US 1999-153406	A 19990910 <--
			US 1999-159783	A 19991015 <--
			CA 2000-2363712	A3 20000517 <--
			CA 2000-2373680	A3 20000517 <--
			CN 2000-807671	A3 20000517 <--

EP 2000-932570	A3 20000517 <--
EP 2000-936023	A3 20000517 <--
JP 2000-618316	A3 20000517 <--
JP 2000-618318	A3 20000517 <--
JP 2000-618327	A3 20000517 <--
JP 2000-619018	A3 20000517 <--
WO 2000-IB763	W 20000517 <--
WO 2000-US13576	W 20000517 <--
US 2000-623543	A1 20000905 <--
US 2000-623548	A1 20000905 <--
US 2000-657276	A2 20000907 <--
US 2000-657332	A3 20000907 <--
US 2000-657431	A1 20000907 <--
US 2002-400199P	P 20020731 <--
US 2002-400413P	P 20020731 <--
US 2002-288340	A1 20021104
WO 2003-CA1097	W 20030729
US 2003-471348	A1 20030908
US 2003-722733	A1 20031125
US 2005-40810	A2 20050121
US 2005-67556	A1 20050225
US 2005-170967	A1 20050629
US 2005-215967	A1 20050830

IT 151679-59-3

RL: PRP (Properties)

(unclaimed sequence; protection of endogenous therapeutic peptides from
peptidase activity through conjugation to blood components)


RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyL-L-glutaminyLglycyl-L-arginyL-L-histidyL-L-
phenylalanyL-L-cysteinyLglycylglycyl-L-alanyL-L-leucyL-L-isoleucyL-L-
histidyL-L-alanyL-L-arginyL-L-phenylalanyL-L-valyL-L-methionyL-L-threonyL-
L-alanyL-L-alanyL-L-seryL-L-cysteinyL-L-phenylalanyL- (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 2-C



ACCESSION NUMBER: 2000:725850 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 133:295374
 TITLE: Lipopolysaccharide immunoassay and test device
 INVENTOR(S): Badley, Robert Andrew; Hughes, Glen; Zak, Krzysztof Wojciech
 PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever N. V.; Hindustan Lever Limited
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060354	A1	20001012	WO 2000-EP2869	20000403 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368975	A1	20001012	CA 2000-2368975	20000403 <--
EP 1166113	A1	20020102	EP 2000-926787	20000403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541457	T	20021203	JP 2000-609793	20000403 <--
AU 763916	B2	20030807	AU 2000-45415	20000403 <--
US 20030054422	A1	20030320	US 2002-131433	20020423 <--
PRIORITY APPLN. INFO.:			EP 1999-302711	A 19990407 <--
			WO 2000-EP2869	W 20000403 <--
			US 2000-545180	A3 20000407 <--

IT 151679-59-3




RL: ARG (Analytical reagent use); BSU (Biological study, unclassified);
 PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL
 (Biological study); USES (Uses)
 (antibody and lipopolysaccharide binding protein for immunodetection of
 lipopolysaccharide and clin. diagnosis of gram-neg. bacterial
 infection)




RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-
 phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
 histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
 L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.





REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:587063 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 133:187935
 TITLE: Antibacterial CAP37 peptides and therapeutic use thereof
 INVENTOR(S): Pereira, H. Anne
 PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA
 SOURCE: U.S., 40 pp.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6107460	A	20000822	US 1999-258934	19990301 <--
US 6514701	B1	20030204	US 2000-619283	20000719 <--
US 20040048792	A1	20040311	US 2002-328125	20021220 <--
US 6730659	B2	20040504		
PRIORITY APPLN. INFO.:			US 1999-258934	A3 19990301 <--
			US 2000-619283	A3 20000719 <--

OTHER SOURCE(S): MARPAT 133:187935

IT 151679-59-3 288855-83-4 288856-01-9
288856-02-0 288856-03-1 288856-10-0
288856-11-1 288856-12-2 288856-14-4
288856-15-5 288856-16-6



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (antibacterial CAP37 peptides and therapeutic use thereof)

RN 151679-59-3 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 288855-83-4 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA AHCFQ



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 288856-01-9 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHFCAGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 288856-02-0 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-




phenylalanyl-L-cysteinyglycyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 NQGRHFCGAA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A










RN 288856-03-1 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCAAA LIHARFVMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 288856-10-0 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-threonyl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHFCGGA LIHARFVMTA ATCFQ



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 288856-11-1 CAPLUS




CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-leucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)



SEQ 1 NQGRHFCGGA LIHARFLMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A









RN 288856-12-2 CAPLUS


CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFIMTA ASCFQ


Absolute stereochemistry.




PAGE 2-A



PAGE 2-B



PAGE 2-C




RN 288856-14-4 CAPLUS
 CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

tyrosyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHYCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 1-C



PAGE 2-A








— SMe




RN 288856-15-5 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-tyrosyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCCGA LIHARYVM TA ASCFQ

Absolute stereochemistry.






RN 288856-16-6 CAPLUS
 CN L-Glutamine, L-asparaginyll-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyll-L-tyrosyl- (9CI) (CA INDEX NAME)


SEQ 1 NQGRHECGGA LIHARFVMTA ASCYQ



Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:291095 CAPLUS <<LOGINID::20081208>>
 DOCUMENT NUMBER: 132:329919
 TITLE: Modified peptides containing an antibody Fc domain as therapeutic agents
 INVENTOR(S): Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
 PATENT ASSIGNEE(S): Amgen Inc., USA
 SOURCE: PCT Int. Appl., 608 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024782	A2	20000504	WO 1999-US25044	19991025 <--
WO 2000024782	A3	20020606		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
 MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6660843	B1	20031209	US 1999-428082	19991022 <--
CA 2347131	A1	20000504	CA 1999-2347131	19991025 <--
EP 1144454	A2	20011017	EP 1999-971003	19991025 <--
EP 1144454	A3	20020911		
EP 1144454	B1	20071212		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK				
CN 1331701	A	20020116	CN 1999-814727	19991025 <--
CN 1310948	C	20070418		
BR 9914708	A	20020716	BR 1999-14708	19991025 <--
HU 2002003506	A2	20030228	HU 2002-3506	19991025 <--
JP 2003512011	T	20030402	JP 2000-578351	19991025 <--
AU 767725	B2	20031120	AU 2000-12322	19991025 <--
NZ 510888	A	20040130	NZ 1999-510888	19991025 <--
NZ 528882	A	20050624	NZ 1999-528882	19991025 <--
CN 1721447	A	20060118	CN 2005-10082591	19991025 <--
CN 1746189	A	20060315	CN 2005-10083696	19991025 <--
CN 100384880	C	20080430		
CN 1746190	A	20060315	CN 2005-10083697	19991025 <--
CN 1781945	A	20060607	CN 2005-10081495	19991025 <--
CN 100384879	C	20080430		
CN 1781946	A	20060607	CN 2005-10081496	19991025 <--
CN 1781947	A	20060607	CN 2005-10081497	19991025 <--
CN 1908014	A	20070207	CN 2005-10081952	19991025 <--
AT 380828	T	20071215	AT 1999-971003	19991025 <--
ES 2299278	T3	20080516	ES 1999-971003	19991025 <--
ZA 2001002753	A	20020611	ZA 2001-2753	20010404 <--
MX 2001PA03873	A	20031014	MX 2001-PA3873	20010417 <--
NO 2001001963	A	20010621	NO 2001-1963	20010420 <--
BG 105461	A	20030430	BG 2001-105461	20010424 <--
HK 1042097	A1	20080403	HK 2002-102701	20020410 <--
US 20040044188	A1	20040304	US 2003-609217	20030627 <--
US 7166707	B2	20070123		
US 20040053845	A1	20040318	US 2003-632388	20030731 <--
US 7189827	B2	20070313		
US 20040071712	A1	20040415	US 2003-645761	20030818 <--
US 20050123548	A1	20050609	US 2003-645784	20030818 <--
US 20040057953	A1	20040325	US 2003-651723	20030829 <--
US 7169905	B2	20070130		
US 20040087778	A1	20040506	US 2003-653048	20030829 <--
US 7186810	B2	20070306		
US 20040077022	A1	20040422	US 2003-666696	20030919 <--
AU 2004200687	A1	20040318	AU 2004-200687	20040220 <--
AU 2004200687	B2	20070510		
AU 2004200690	A1	20040318	AU 2004-200690	20040220 <--
AU 2004200690	B2	20070510		
AU 2004200691	A1	20040318	AU 2004-200691	20040220 <--
AU 2004200691	B2	20070329		

US 20060234307	A1	20061019	US 2006-472070	20060620 <--
JP 2007084555	A	20070405	JP 2006-288325	20061024 <--
JP 2007084556	A	20070405	JP 2006-288346	20061024 <--
JP 2007084557	A	20070405	JP 2006-288383	20061024 <--
JP 2007084558	A	20070405	JP 2006-288397	20061024 <--
JP 2007091746	A	20070412	JP 2006-288324	20061024 <--
JP 2007091747	A	20070412	JP 2006-288347	20061024 <--
JP 2007089586	A	20070412	JP 2006-288382	20061024 <--
JP 2007105044	A	20070426	JP 2006-288398	20061024 <--
US 20070049532	A1	20070301	US 2006-591002	20061031 <--
KR 2007050977	A	20070516	KR 2007-706958	20070327 <--
KR 2007050978	A	20070516	KR 2007-706961	20070327 <--

PRIORITY APPLN. INFO.:

US 1998-105371P	P	19981023 <--
US 1999-428082	A	19991022 <--
AU 2000-12322	A3	19991025 <--
CN 1999-814727	A3	19991025 <--
JP 2000-578351	A3	19991025 <--
WO 1999-US25044	W	19991025 <--
US 2000-563286	A1	20000503 <--
KR 2001-704982	A3	20010420 <--
US 2003-645761	A3	20030818
US 2003-666696	A1	20030919
AU 2004-200687	A	20040220

IT **151679-59-3D**, fusion protein with IgG1 Fc domain
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (CAP37 mimetic/LPS binding; modified peptides containing an antibody Fc domain as therapeutic agents)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteiny-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCCGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

